Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study

Lung Cancer

Volumn 88, Issue 2, 2015, Pages 215-222

  Moro Sibilot, Denis ^a   Smit, Egbert ^b   de Castro Carpeño, Javier ^c   Lesniewski Kmak, Krzysztof ^d   Aerts, Joachim ^e,f   Villatoro, Rosa ^g   Kraaij, Kees ^h   Nacerddine, Karim ^h   Dyachkova, Yulia ⁱ   Smith, Karen T ^h   Taipale, Kaisa ^j   Girvan, Allicia C ^h   Visseren Grul, Carla ^h   Schnabel, Philipp A ^k  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e AMPHIA HOSPITAL   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g HOSPITAL COSTA DEL SOL   (Spain)

^h ELI LILLY AND COMPANY   (United States)

ⁱ Eli Lilly GmbH   (Austria)

^j Eli Lilly GmbH ^*  (Finland)

^k UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

more..

Author keywords

Health resources; Non small cell lung cancer (NSCLC); Observational study; Survival

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; NAVELBINE; OXALIPLATIN; PEMETREXED; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; PLATINUM COMPLEX; TAXOID; VINBLASTINE;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; EUROPE; LUNG NEOPLASMS; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; EUROPE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PEMETREXED; PROSPECTIVE STUDIES; TAXOIDS; VINBLASTINE;

EID: 84926415720     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.02.011     Document Type: Article

References (29)

1. Cufer T., Ovcaricek T., O'Brien M.E. Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur J Cancer 2012, 49:2815-2822.
2. Goffin J., Lacchetti C., Ellis P.M., Ung Y.C., Evans W.K. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 2010, 5:260-274.
3. Peters S., Adjei A.A., Gridelli C., Reck M., Kerr K., Felip E. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl. 7):vii56-vii64.
4. Felip E., Gridelli C., Baas P., Rosell R., Stahel R. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 2011, 22:1507-1519.
5. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
6. Clements K.M., Peltz G., Faries D.E., Lang K., Nyambose J., Earle C.C., et al. Does type of tumor histology impact survival among patients with stage IIIB/IV non-small cell lung cancer treated with first-line doublet chemotherapy?. Chemother Res Pract 2010, 2010:524629.
7. Hoang T., Dahlberg S.E., Schiller J.H., Johnson D.H. Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594. Lung Cancer 2013, 81:47-52.
8. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253-263.
9. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
10. Scagliotti G., Brodowicz T., Shepherd F.A., Zielinski C., Vansteenkiste J., Manegold C., et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011, 6:64-70.
11. Ardizzoni A., Boni L., Tiseo M., Fossella F.V., Schiller J.H., Paesmans M., et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007, 99:847-857.
12. Schnabel P.A., Smit E., Carpeño J.D., Leśniewski-Kmak K., Aerts J., Kraaij K., et al. Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME). Lung Cancer 2012, 78:263-269.
13. Besse B., Adjei A., Baas P., Meldgaard P., Nicolson M., Paz-Ares L., et al. 2nd ESMO consensus conference on lung cancer: non-small-cell lung cancer first-line/second and further lines in advanced disease. Ann Oncol 2014, 25:1475-1484.
14. AJJC cancer staging manual 1997, Lippincott-Raven, Philadelphia, PA. 5th ed. I.D. Fleming, J.S. Cooper, D.E. Henson, R.V.P. Hutter, B.J. Kennedy, G.P. Murphy, B. O'Sullivan (Eds.).
15. Scagliotti G.V., De Marinis F., Rinaldi M., Crinò L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
16. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A., Albain K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999, 341:2061-2067.
17. Meoni G., Cecere F.L., Lucherini E., Di Costanzo F. Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents. J Geriatr Oncol 2013, 4:282-290.
18. Sacher A.G., Le L.W., Leighl N.B., Coate L.E. Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC?. J Thorac Oncol 2013, 8:366-368.
19. Gospodarowicz M.K.G.P., O'Sullivan B., Sobin L.H., Koh E.-S. Staging of cancer. Prognostic factors in cancer 2006, Wiley-Liss, New Jersey, USA. 3 ed. M.K.O.S.B. Gospodarowicz, L.H. Sobin (Eds.).
20. Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003, 21:3016-3024.
21. Carrato A., Vergnenegre A., Thomas M., McBride K., Medina J., Cruciani G., et al. Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study. Curr Med Res Opin 2014, 30:447-461.
22. Eli Lilly and Company, Indianapolis, IN; EMA Alimta Label. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000564/WC500025611.pdf.
23. Eli Lilly and Company, Indianapolis, IN; EMA Gemzar Label. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Gemzar_30/WC500008487.pdf.
24. Aventis Pharma S.A., Docetaxel EMA Label. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000073/WC500035264.pdf.
25. Actavis UK Ltd, paclitaxel label. http://www.medicines.org.uk/emc/medicine/24064/SPC/Paclitaxel+6mg+ml+Concentrate+For+Solution+For+Infusion/.
26. CP Pharmaceuticals Ltd, Vinorelbine Label. http://www.mhra.gov.uk/home/groups/lunit1/documents/websiteresources/con2024222.pdf.
27. Eli Lilly and Company I, IN ALIMTA first chemotherapy approved in Europe as continuation maintenance therapy for most common form of lung cancer 2011, https://investor.lilly.com/releasedetail.cfm?ReleaseID=618852.
28. Eli Lilly and Company I, IN ALIMTA(R) (pemetrexed for injection) first agent approved in Europe as maintenance therapy for advanced, nonsquamous non-small cell lung cancer 2009, https://investor.lilly.com/releasedetail.cfm?releaseid=395577.
29. Luengo-Fernandez R., Leal J., Gray A., Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013, 14:1165-1174.